Top 8 Advantages of Electroporation in Cell and Gene Therapy
Cell and gene therapies have seen record growth due to their potential to address the underlying causes of genetic and acquired diseases. Non-viral delivery methods are increasing in popularity due to their safety, cost-effectiveness, reduction in manufacturing time, and flexibility compared to viral vector delivery methods. Electroporation is a simple, broadly applicable method capable of delivering molecules to a wide range of cell types for either cell or gene therapy. This article outlines the top advantages of using electroporation in cell and gene therapy and why it might be a good approach for your own research group.
Manufacturing a Recombinant Retrovirus — Downstream Purification Process Development
Enveloped virus and VLP purification can be difficult. Learn about key factors and a cGMP-compatible, low cost, scalable process for retrovirus vector capture.
CDMOs Drive Cell and Gene Therapy from Behind the Scenes
As more of the cell and gene therapies revolutionizing healthcare are approved for use, innovator companies usually get the credit. But many therapies would never make it to market without the expertise and capabilities of contract development and manufacturing organizations (CDMOs) operating behind the scenes. Learn more about how CDMOs enable new cell and gene therapies to come to market, and how Droplet Digital PCR can help.
The Role of ddPCR in Developing Safe and Effective AAV-Based Gene Therapies
Developing adeno-associated virus (AAV)-mediated gene therapies requires accurate and precise quality control. Read how Droplet Digital PCR technology provides the sensitivity needed to assess the potential safety and effectiveness of these treatments.
Top 5 Challenges Faced by AAV Developers Today
Adeno-associated viruses (AAVs) are some of the most commonly used viral vectors for gene therapy, supporting approximately 250 clinical trials to date. However, the manufacturing processes are challenging to scale. Read about five key issues that gene therapy manufacturers who use AAVs need to look out for.
Expert Coffee Chats: Coffee Chat #4 – Droplet Digital PCR in Cell and Gene Therapy
Presented by: Matthew L. Turner, PhD, Field Application Scientist – ddPCR, NGC and qPCR, Tara Ellison, PhD, Senior Field Application Scientist
Date: June 17, 2020
Time: 9 AM, U.S. Pacific time
- Robust methodology for viral titer using ddPCR
- Precise copy number determination & improved confidence in acceptance criteria
- Enhance your throughput and minimize hands-on time
- Learn how ddPCR is used in other key applications